RLMD
Relmada Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RLMD
Relmada Therapeutics, Inc.
A late-stage biotechnology company that addressing diseases of the central nervous system
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134
--
Relmada Therapeutics, Inc., a privately held company, was incorporated in May 2004. The company is a clinical-stage biopharmaceutical company focused on developing drug candidates for the treatment of chronic pain. The company is focused on the development of d-methadone (dexmethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Methadone is a new chemical entity that may address areas of unmet medical need in the treatment of central nervous system (CNS) diseases and other diseases.
Company Financials
EPS
RLMD has released its 2025 Q3 earnings. EPS was reported at -0.3, versus the expected -0.45, beating expectations. The chart below visualizes how RLMD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
